Lobe Sciences Ltd.

Recent News

• Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company

  Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments and Commercial Inventory and Intellectual Property.Vancouver, British Columbia--(Newsfile Corp. - June 30, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American...

  2023-06-30 10:03 PM EDT
• Lobe Sciences, Ltd. Provides Update on Vitamind

  Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Brand and intellectual property ("Vitamind") pursuant to an asset purchase agreement dated April 30, 2021 (the "Agreement"). Pursuant to the Agreement, the Company issued 2,916,668[1] common shares to acquire Vitamind. The Agreement specified...

  2023-04-21 5:00 PM EDT
• Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company

  Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments, Commercial Inventory and Intellectual Property.Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical...

  2023-04-18 8:58 AM EDT
• Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

  Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, will present at the SEQUIRE CANNABIS & PSYCHEDELICS CONFERENCE, April 5th at 10:00AM EDT.Registration for the event is accessible via the following link Sign up free.About Lobe Sciences Ltd.Lobe Sciences is a biopharmaceutical company focused...

  2023-04-04 8:00 AM EDT
• Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

  Vancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its exclusive commercial manufacturing partner has received their initial 2023 quota for our novel psilocin drug product (L-130) from the Drug Enforcement Administration (DEA). Mr. Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "This is...

  2023-03-22 9:01 AM EDT
• Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC

  Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arrangement Lobe Sciences Ltd. and QCL have entered into an agreement for the development of commercial formulations of L-130 for the treatment of chronic cluster headacheVancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB:...

  2023-02-21 8:30 AM EST
• Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance

  Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,000. This investment will be in the form of a convertible note (the "Note") with a face value of USD $250,000 and simple interest at the annual rate of 11.0% per annum. The...

  2023-02-10 5:03 PM EST
• Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA

  Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today congratulated the people of Australia for the decision by the TGA (Therapeutic Goods Administration) to reschedule Psilocybin and MDMA so that trained physicians may prescribe the psychedelics for patients across the country.Philip J. Young, Chairman and Chief Executive Officer of the...

  2023-02-06 8:00 AM EST
• Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache

  Vancouver, British Columbia--(Newsfile Corp. - January 26, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease, today announced that it has signed an Investigator Initiated Research Agreement with Lauren R. Natbony, MD, FAHS, Founder and Medical Director of Integrative Headache Medicine of New York, to study the tolerability and efficacy of our proprietary psilocin compound L-130, in patients...

  2023-01-26 8:30 AM EST
• Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees

  Endorsement underscores transition into a fully integrated biotechnology companyVancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced its Board of Directors voted to receive shares in Lobe in lieu of the traditional cash renumeration. Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "This is a...

  2023-01-23 9:00 AM EST